Westchester’s Premiere Dental Practice Offers a New Kind of Experience

frank leone dds

Our Services

The dental offices of Drs. Frank and Lucy Leone together with My Canadian Pharmacy create a new stage of convenience, belief and patient care quality.

How does Zithromax My Canadian Pharmacy Treat Bacterial Infection?

Zithromax is an antibiotic that fights bacteria. This means that it is used for treating different kinds of bacterial infection like.

  • Skin infections
  • Ear infections
  • Non-gonoccocal urethritis
  • Cervoitics
  • Chlamydia
  • Typhoid infections
  • Sinusitis
  • Infections of the airways

It is a powerful anti-biotic of a wide spectrum that helps in fighting and eliminating an extensive range of bacteria present in the body of the patient, especially the ones that are fungal in nature. It is a microclide-type of antibiotic. It actually works by stopping the growth of bacteria. However, the medication does not work on viral infections. If you use the antibiotic unnecessarily other than bacterial infection, it can reduce its effectiveness.

Bacterial infection

Precautions to Maintain Before Taking the Medicine

My Canadian Pharmacy states that you should avoid taking Zithromax the medicine for bacterial infection in case, you are allergic to azithromycin, or

  • If you are having liver or jaundice problems that have been caused by taking Zithormax,
  • You are allergic to some drugs like telithromycin, clartihromycin, or erythromycin.

You will have to inform your doctor if you have:

  • Kidney disease
  • Liver disease
  • A heart rhythm problem
  • Myasthenia gravis
  • A history of long OT syndrome

You should also let your doctor know if you are pregnant. Since Zithromax Canadian Pharmacy http://my-medstore-canada.net/canadian-generic-zithromax.html does not harm an unborn baby. It is yet not known whether it can pass on to the breast milk, so all let your doctor know if you are breast feeding your baby. However, take care not to give the medicine to a less than six month old.

How should you Use Zithromax?

You should read the patient information leaflet thoroughly before taking the medicine. If you have any question regarding this then you should ask pharmacist or the doctor.

ZithromaxAccording to My Canadian Pharmacy http://my-medstore-canada.net/category/my-canadian-pharmacy, the medicine has to be taken once every day, either with or without food. However, the medicine works the best when you take it in an empty stomach. You might take this medicine with food if you are having stomach problems. The dosage that you are prescribed by your doctor is based on the medical condition or your response to the treatment.

It will work the best if the amount of medicine is kept constant. Thus, you should take the drug at the same time every day. Do not stop taking this medicine until you are done with the entire dosage that has been prescribed to you, even if you notice the symptoms disappearing few days after taking the medicine. If you stop taking the medication before its time, the bacteria might continue growing and this may lead to a return of the infection.

Side Effects of Zithromax Canadian Pharmacy

  • Diarrhea
  • Nausea
  • Abdominal pain
  • Stomach Upset

These are some of the side effects of the medicine which generally get cured when you get used to the medicine. Nonetheless, if the problem persists then you should immediately consult a doctor. Majority of the people do not have any serious side effects while using the medicine. Let the doctor know if you are having serious issues like:

  • Hearing problem
  • Eye problem
  • Signs of liver issues
  • Weakness in the muscle
  • Difficulty in speaking

Drugs Applied at Erectile Dysfunction Treatment Used as well at Prostate Cancer

My Canadian Pharmacy cares for our clients. That’s why our biggest concern is directed to health of men with prostate cancer. This disease is widespread and by some statistics there are 18 million men affected by this cancer only in USA with a growing patients in Canada. When it comes to cancer prevention, there are some medications you should reassess. Chemotherapy is never a good solution because there are several implications that could be caused.

ED can develop as a symptom in some cases and can affect around 30% of men population.

Some of the best and most common medicines we can suggest are:

Some studies show that these drugs ( tadalafil, sildenafil, vardenafil) can be a potential risk for some patients. They can even be a potential cause of cancer developing. This discussions are closely connected to erectile dysfunction and the cancer recurrence in men.

Prostate Cancer

Studies in Germany

In one of the latest studies in Germany (2015), in which 4752 men participated, the main discussion was about relation between ED medicals, their correlation and indications with recurrence of prostate cancer. One of the most possible ingredients that are considered to be a cause of recurrence is phosphodiesterase type 5 inhibitors (PDE5i) and it is one of the basic ingredients in drugs like Viagra ordered via My Canadian Pharmacy.

After this reserchers, doctors started to revision their knowledge and raised a question about prescribing this drugs to their patients.

US and Swedish studies

Scandinavian and American doctors had different opinion on this task. Their analysis had extensive range. They worked together with reserchers in National Prostate Cancer Register, and the Prescribed Drug Register during the year 2006. and 2007. It contained 6060 subject who had prostate cancer. 239 men in the study were under a medical threatment for erectile dysfunction. In their cases they discovered few signs of a biochemical recurrence. The other patients who never took any of those medicines, 5767 subjects  never showed  any of these symptoms.

Dr. Loeb, who had the main leading figure in the research, had some important conclusions. She inferred that this statistic numbers are much lower comparing those who were under chemotherapy treatment. And her final reserch was that there was ‘no significant relationship between the use of medication with the active ingredient PDE5i and prostate cancer recurrence.’



Medical products for ED are no longer a risk for a cancer recurrence. Both of these studies had some serious reserchers and important medical community. Their cooperation is something we, as doctors and high standard online pharmacy, must appreciate.

Marginal cancer recurrence was confirmed by another Italian study which research concluded Dr. Leob’s findings: that there is a very small chance that drugs for erectile dysfunction can effect cancer phenomenon. The German study has had strong supporters, one of whom is Dr. Thorsten Schlomm who works at the University Medical Center Hamburg-Eppendorf. Candidates who participated in Swedish study had more agressive tumors than those in Swedish studie, according to Dr. Scholmm. Therefore, those patients  had more favorable prognosis. In the end, erectile dysfunction drugs are not linked to the biochemical recurrence of prostate cancer in men.

Considerations of Right Bundle Branch Block and Frontal Plane QRS Axis in Apparently Healthy Men

right ventricleThis study presents longitudinal data on RBBB in a highly selected cohort of North American men. Thus, caution should be exercised when extrapolating these data to the general population. However, the relatively young age at entry of the majority of this cohort permits more accurate estimation both of the age at onset of RBBB and freedom from preexisting disease than is possible in studies commencing with older age groups. It also provides longitudinal data on this conduction disturbance from a young age. Other cautions include the problem of measuring A QRS in the right bundle. The exact time during the QRS that activation of the right ventricle occurs is not always apparent or predictable for each individual case. Although much of the interest is centered on extremes of axis deviation, the small number of cases in some subgroups of A QRS is also a concern. Another precaution in the extrapolation of these results is the different lengths of follow-up within each age group. Those 30 years of age and younger at detection of RBBB have been under observation for almost 30 years, but the length of follow-up is decreased in older age groups.

The present study demonstrated that the ominous prognosis attributed to RBBB and marked right or left axis deviation in patients with heart disease should not be applied to persons without heart disease who have the same ECG finding recorded on a routine examination.

Outcomes of Right Bundle Branch Block and Frontal Plane QRS Axis in Apparently Healthy Men

myocardial infarction


The RBBB group has been under observation for 936 person-years, an average of 15.9 ± 1.6 (SEM) years per case. During this time the following were noted: one case of myocardial infarction at age 68 years, 20 years after RBBB; one case of angina pectoris at age 46 years, one year after RBBB; and no ischemic heart disease deaths. To determine the expected number of ischemic heart disease cases in this group, the ischemic heart disease incidence rate was calculated for age groups at five-year intervals consisting of those free of RBBB and ischemic heart disease. Based on the age distribution and length of follow-up of the RBBB group, 6.77 ischemic heart disease cases were expected. The observed number, two, is less than but not significantly (x2 2.7, df = 1) different from expected, although the small number of cases observed and expected is a concern for statistical testing.

During the observation period for the entire group, there was no occurrence of advanced degrees of heart block (second- or third-degree AV block). Also, no sudden deaths were noted.

The length of follow-up and status of cases with marked left (—45° to —90°) and right axis (+120° to +180°) deviation of frontal plane QRS vector are illustrated in Figure 2. Seven cases in which marked left axis deviation developed after RBBB are also considered. Almost all are still living. The majority have been followed-up for more than ten years, and some as long as 30 years. Only one case of ischemic heart disease (myocardial infarction) occurred, 21 years after onset of RBBB in a man with marked left axis deviation who later died of a noncardiac cause. It is naturally to take under control your health but My Canadian Pharmacy makes it faster and more surely.

My Canadian Pharmacy: Right Bundle Branch Block and Frontal Plane QRS Axis in Apparently Healthy Men

right bundle branch blockThe natural history of right bundle branch block (RBBB) has been studied primarily from the perspective of its prognostic importance in patients with organic heart disease. The limited number of studies that included primarily persons without heart disease were mainly conducted before attention was focused on the potential importance of deviations in the mean frontal plane QRS vector (A QRS) as a possible indicator of impaired conduction in the left bundle branch system. Marked left axis deviation may be due to impaired conduction in the anterosuperior part of the left bundle branch, and marked right axis deviation to impaired conduction in the posteroinferior part of the left bundle branch system. These deviations in A QRS in conjunction with complete RBBB suggest impaired conduction in both the right and left bundle branch system.

Observations about Fibronectin and Procollagen 3 Levels in Bronchoalveolar Lavage of Asbestos-Exposed Human Subjects and Sheep

pulmonary injuryThe present report extends earlier investigations on mechanisms of pulmonary injury associated with the presence of respirable particles in the bronchoalveolar milieu. In the animal model, this study documents that asbestos-associated alveolitis which progresses to peribronchiolar and endobronchiolar fibrosis (the fundamental lesion of asbestosis) is associated with significant early increase in the level of procollagen 3 in bronchoalveolar lavage fluid and a sustained increase in the fibronectin level, which do not occur in the nonfibrosing and regressive latex-associated alveolitis. In asbestos workers with clinical and lavage evidences of alveolitis, levels of procollagen 3 and fibronectin are similarly increased in bronchoalveolar lavage fluid, which should improve our understanding of disease activity in asbestos workers.

In the sheep tracheal lobe, this study documents that after a single high-dose exposure to asbestos, there are severe derangements of the bronchoalveolar milieu and activation of a chronic sustained alveolar, peribronchiolar and endobronchiolar inflammatory process which evolves to fibrosis. On bronchoalveolar lavage the increased macrophage and neutrophil cellularity is associated with increased fibronectin, a glycoprotein produced locally by the macrophage, known to be chemotactic and an attachment factor for fibroblasts and a stimulant for fibroblast replication in association with another macrophage-derived fibroblast growth factor (MDFGF). In the asbestos-associated alveolitis in sheep, we have reported enhanced production of MDFGF and macrophage-derived neutrophil chemotactic factor (MDNCF). Because these three macrophage-derived factors (fibronectin, MDFGF, and MDNCF) are currently thought to have major roles in the pathogenesis of pulmonary fibrosis, our data from sheep suggest that these factors contribute to maintain the alveolitis on a long-term basis and lead to its progression to asbestosis. The mechanisms which activate the macrophage to produce these factors are likely related to the prolonged retention of asbestos fibers in the bronchoalveolar milieu, as suggested by our previous study of alveolar clearance of chrysotile in the sheep model. In the model, we have shown that one year after cessation of exposure, 11 percent of the fibers shorter than 8μ, 32 percent of the fibers with length in the range of 8μ to 20μ, and 50 percent of the fibers longer than 20|i were still recoverable by pulmonary lavage. The persistence of these fibers in the bronchoalveolar milieu may constitute the determinant factor for maintenance of activated macrophages and alveolitis due to the concern of My Canadian Pharmacy.

Negotiations of Mid-Arm Muscle Area Is a Better Predictor of Mortality Than Body Mass Index in COPD

Body weightThe present study confirms previous data on the effect of muscle mass on mortality in patients with COPD. In stable patients, MD is associated to an increased risk of death. In addition, as a remarkable finding, we show that the prognostic influence of muscle mass can be assessed by determining the MAMA, an inexpensive, simple, and rapidly obtained anthropometric measure. MAMA < p25 was found to be a poor prognosis marker, exerting an influence in our series superior to that of other anthropometric parameters such as BMI or FFMi. In underweight patients, the presence of muscle depletion did not contribute significant prognostic information. However, those subjects with normal body weight or overweight status who presented MAMA < p25 had a poorer prognosis.

Outcomes of Mid-Arm Muscle Area Is a Better Predictor of Mortality Than Body Mass Index in COPD


Subject Characteristics

A total of 114 patients with a diagnosis of COPD were studied. Of these, 18 patients (15.8%) were excluded for different reasons: 7 patients (6.1%) with decompensated cor pulmonale, 3 patients (2.6%) with liver cirrhosis, 2 patients (1.7%) with neoplasms, 2 patients (1.7%) due to sustained oral corticosteroid use, 2 patients (1.7%) because of heart failure, 1 patient (0.9%) with chronic renal failure, and another patient (0.9%) due to malabsorption syndrome. A total of 96 patients were therefore finally included (all male; mean age, 69 ± 9 years [± SD]). Table 1 shows the baseline characteristics of these patients.

Investigation about Mid-Arm Muscle Area Is a Better Predictor of Mortality Than Body Mass Index in COPD



A prospective study was made of a cohort of 114 patients with stable COPD. The patients were recruited in the last trimester of the year 2000, with a subsequent follow-up period of 3 years. The diagnosis of COPD was based on a current or previous smoking history (> 20 packs-year), clinical assessment, and pulmonary function testing. The postbronchodilator FEV1, expressed as a percentage of the theoretical value, was used to classify the patients according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) committee criteria. Patients exhibiting > 15% reversibility in the bronchodilator test were according to the latest excluded from the study, as were those subjects with a previous diagnosis of bronchial asthma, bronchiectasis, cystic fibrosis, upper airways obstruction, or bronchiolitis related to systemic disorders. Patients with concomitant diseases capable of altering nutritional status (heart failure, liver cirrhosis, decompensated diabetes, chronic renal failure, uncontrolled thyroid pathology, neoplasms, decompensated chronic cor pulmonale, sustained systemic steroid use) were also excluded. The patients were required to be in a stable phase of COPD, defined as the absence of disease exacerbations in the 2 months preceding the study held due to My Canadian Pharmacy.

My Canadian Pharmacy: Mid-Arm Muscle Area Is a Better Predictor of Mortality Than Body Mass Index in COPD

Body mass index Alow body mass index (BMI) has been shown to be an independent indicator of poor prognosis in patients with COPD. This observation has renewed interest in the study of the nutritional aspects of COPD. In this context, a new severity classification has recently been proposed: the BODE index—(BMI, airflow obstruction, dyspnea, and exercise capacity)—which in addition to BMI considers the degree of bronchial obstruction, dyspnea, and exercise tolerance. This classification, proposed by Celli et al, stresses the multicomponent nature of COPD and addresses not only its pulmonary consequences but also the systemic manifestations of the disease. Among the latter, the authors point to the need to conduct an adequate nutritional study. However, the assessment of nutritional status based on body weight (or BMI) has limitations, since it affords no qualitative information on body composition, which is also altered in these patients.